News | April 27, 2023
Syngene International posts Q4 FY2023 consolidated profit at Rs. 178.7 Cr
The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023
The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023
The acquisition is a crucial step in LTS' strategy to broaden its portfolio of drug delivery platforms.
WuXi Bio provided technical services, based on the companies' versatile integrated service platforms, to support various manufacturing and process development activities of these ADC product candidates.
Acceptance based on results from the Phase 3 KEYNOTE-859 trial, which showed significant overall survival benefit in these patients with HER2-negative disease, regardless of PD-L1 expression
FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop
Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution
For the year 2022, Biocon bettered its score in all the four EcoVadis themes – Environment (70), Labor & Human Rights (70), Ethics (60), and Sustainable Procurement (60)
The Congress gathers the whole value chain of the pharmaceutical industry on June, 12-13, 2023 in Switzerland
Proposed combination enhances Pfizer’s position as a leading company in oncology
Julian Collins, Jana Windt and Michiel Stork join biopharma company’s leadership team
Subscribe To Our Newsletter & Stay Updated
